TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cumulative postoperative analgesic consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog pain scores
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Intraoperative HBL and IBL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TED (Time to Exercise Duration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual acuities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary expression levels of miR‐6807‐5p and miR‐6856‐5p for diagnosis of GC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of biomarker panel (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in FCS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Schirmer test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TBUT, LGCS scores, and OSDI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary levels of 1‐methylhistidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary levels of 3‐methylhistidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bronchial hyper-responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: sputum neutrophil count reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Integrated service capacity for persons with co-occurring disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean BCVA after 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutrient profiling score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy cost per 418 kJ (100 kcal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in mean peak oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of predefined UGI and cardiovascular AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Median total treatment time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Collision risk requiring technical adaptation
Endpoint domain: Adverse events/effects
Primary endpoint: Dose to structures outside the target area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean trial‐patient difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes in MBML
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of vaginal discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VHI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FSFI Total Score
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: sum score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean daily doses of fluticasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with IOP above 30 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Reaction time to warnings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of the warning system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disturbance rating of warnings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSA of the median nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ACTH secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ACTH burst mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Secretion regularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Occurrence of major adverse cardiac and cerebrovascular events
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from VT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Burden of VT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Shift of melanocytes into the corium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in SPA
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: visual analog scale score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance (CL) of (R)‐ and (S)‐warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of PGD2 induced bronchoconstriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Length of the operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cosmetic outcome of skin flaps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LEP-amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Thenar cold pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Supra-threshold heat pain rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glucose tolerance improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intra-observer agreement (κ statistic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-observer agreement (κ statistic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month incidence of prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: cumulative risk of prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Metacognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to sheath removal and ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Trop I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peri‐procedure Trop I elevation
Endpoint domain: Adverse events/effects
Primary endpoint: increase in appetite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in calorie intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in muscular strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in vitamin levels (B12, B3, B5, D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete remission from neoplasia at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: recurrence of EAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: restlessness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean annual change in estimated GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean annual change in creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of physicians feeling adequately trained
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Absolute mean improvement in risk factor identification score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean proportion of patients per physician stating they were advised to watch their moles
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Segmental and extrasegmental hypoalgesic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival rates of restorations
Endpoint domain: Mortality/survival
Primary endpoint: Oligohydramnios cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Serum Cortisol (SC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean serum LH level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean serum E2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean HP dosage per treatment cycle
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pocket depths 4 mm or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall use of any effective contraception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: use of long‐acting contraceptive methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lysholm Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Detection rate of sentinel lymph nodes (SLN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False-negative rate to identify pN+ patients by SLNB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of SLNB in slim patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of registration methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of residual neuromuscular block (TOF ratio < 0.7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: Time to TOF ratio reaching 0.8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visibility of laryngeal structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Long term potentiation-like effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Aesthetic outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: verbal recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response rates to follow-up questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Depression symptoms (HAMD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cognition function (FIM)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maternal systolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neonatal respiratory depression episodes
Endpoint domain: Adverse events/effects
Primary endpoint: END (Early Neurological Deterioration)
Endpoint domain: Mortality/survival
Primary endpoint: total clinical cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximal omeprazole concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal concentration of omeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability of pharmacokinetic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global dissatisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Level of involvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Clinical hepatotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: psychopathologic outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sunburns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: CAI agreement with CRBSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: time to first event of any stroke or TIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difficulties with IADLs
Endpoint domain: Life impact
Endpoint subdomain: Functional functioning
Primary endpoint: Depressive symptom levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of PONV requiring rescue antiemetic
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality rates at 90 days after ICH onset
Endpoint domain: Mortality/survival
Primary endpoint: Functional outcomes at 90 days after ICH onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: periodontal attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distance of CEJ to the bone defect bottom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: avidity of serum IgG against Pg LPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Asystole
Endpoint domain: Adverse events/effects
Primary endpoint: latency to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Children's anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Contraception counselling received
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rating of clinical skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CD4 T-cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Grade 2 or worse general body symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Gallstone formation
Endpoint domain: Adverse events/effects
Primary endpoint: Any breastfeeding rate at 6 weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Capability for intercourse
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Return to baseline IIEF-6 EF domain score
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Return to IIEF-6 > 17
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Complete delayed protection from nausea and vomiting (DCPNV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete control rates of vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrences of constipation
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrences of abdominal distention
Endpoint domain: Adverse events/effects
Primary endpoint: Survival after TIPS
Endpoint domain: Mortality/survival
Primary endpoint: Assisted shunt patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: VEGFS levels in cancer patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VEGF levels in citrated plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PF4 levels in citrated plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: yearly rates of appropriate shock
Endpoint domain: Adverse events/effects
Primary endpoint: failed appropriate first shock
Endpoint domain: Adverse events/effects
Primary endpoint: composite of failed shock or arrhythmic death
Endpoint domain: Adverse events/effects
Primary endpoint: self-reported psychological stress reactivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of angina pectoris
Endpoint domain: Mortality/survival
Primary endpoint: Hospitalization due to acute coronary syndrome (ACS) attacks
Endpoint domain: Mortality/survival
Primary endpoint: Serum levels of IL-6 and MMP-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival free of BPD
Endpoint domain: Mortality/survival
Primary endpoint: quicker recession of clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of hearing estimated in tonal audiometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: improvement of impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Completion of robotic single-site cholecystectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Average operating room time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach deep sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of alpha-carotene and vitamin E
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum concentration of vitamin C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Provocative concentration of AMP causing a 20% fall in FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood eosinophil count (EOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rescue bronchodilator requirement (RES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MBI (Modified Barthel Index)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SSQOL (Stroke Specific Quality of Life)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement of HAMD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of Barthel index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of spleen and stomach symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hydration status indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔO2Hb concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔtotalHb concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: REFLUX score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach final dose of carvedilol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute reduction in adverse periprocedural outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: mortality by 6-month follow-up
Endpoint domain: Mortality/survival
Primary endpoint: absolute in-hospital complication rates
Endpoint domain: Adverse events/effects
Primary endpoint: Nutrition-related knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Nutrition-related skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Likelihood of snack consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BD response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Gastric emptying of solids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microvessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean BCVA gains from baseline to week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of eyes gaining ≥ 15 letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reductions in central retinal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gallbladder perforation
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative pain (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: high-sensitivity C-reactive protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: normal response in the oral glucose tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Circulating leptin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean total tremor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean activities of daily living (ADL) subscore
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total number of harvested lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean depression score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes